phrykt

Enanta Pharmaceuticals Inc (ENTA): who owns it and who trades it

As of Nov 16, 2026, ENTA insiders reported 9 open-market sales worth $183K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jay R. Luly (CEO), with $67.5K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Enanta Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ENTA

121 funds and institutions reported ENTA shares worth $402M at the end of Q2 2026, about 95% of the company. The largest holder is Jupiter Topco LLC with 12.6%.

Funds and institutions (13F) 95%Everyone else 5%

10 largest owners, by share of the company

Jupiter Topco LLC12.6%
BlackRock, Inc.11.2%
Krensavage Asset Management, LLC9.9%
Farallon Capital Management, L.l.c.8.3%
Deep Track Capital, LP5.0%
ADAR1 Capital Management, LLC4.6%
Vanguard Capital Management LLC4.2%
Spruce Street Capital LP3.7%
Acadian Asset Management LLC3.7%
Vanguard Portfolio Management LLC3.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Jupiter Topco LLC3.65M12.57%$53.3M–
BlackRock, Inc.3.24M11.16%$47.3M+5%
Krensavage Asset Management, LLC2.87M9.86%$41.8MNo change
Farallon Capital Management, L.l.c.2.42M8.32%$35.3M-16%
Deep Track Capital, LP1.44M4.97%$21.1M-26%
ADAR1 Capital Management, LLC1.34M4.62%$19.6M+2518%
Vanguard Capital Management LLC1.21M4.17%$17.7M+3%
Spruce Street Capital LP1.09M3.74%$15.9M+17%
Acadian Asset Management LLC1.08M3.71%$15.7M+23%
Vanguard Portfolio Management LLC1.01M3.48%$14.7M+7%
Geode Capital Management, LLC776,6342.67%$11.3M+7%
Millennium Management LLC643,9672.21%$9.4M-27%
State Street Corp576,1171.98%$8.4M+2%
Renaissance Technologies LLC557,6001.92%$8.1M-16%
Hillsdale Investment Management Inc.468,0001.61%$6.8M+7%
Goldman Sachs Group Inc464,6491.60%$6.8M+75%
Morgan Stanley315,7291.09%$4.6M+2%
Charles Schwab Investment Management Inc301,1511.04%$4.4M+2%
Sixth Street Partners Management Company, L.P.301,1511.04%$4.4M–
Dimensional Fund Advisors LP282,6820.97%$4.1M+39%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ENTA insiders reported $0 of open-market purchases and $183K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$183K
9 trades, 7 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Dec 5, 2025
Filed Dec 5, 2025

Purchases and sales by month

$183K$183KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Dec 5, 2025Kathleen S. CappsSee RemarksSale323$14.23$4.6KForm 4
Dec 5, 2025Harry R. Trout IIISee RemarksSale542$14.23$7.7KForm 4
Dec 5, 2025Scott T. RottinghausChief Medical OfficerSale798$14.23$11.4KForm 4
Dec 5, 2025Brendan LuuChief Business OfficerSale1,394$14.23$19.8KForm 4
Dec 5, 2025Tara Lynn KiefferChief Product Strategy OSale2,106$14.23$30KForm 4
Dec 5, 2025Yat Sun OrChief Scientific OfficerSale2,390$14.23$34KForm 4
Dec 5, 2025Jay R. LulyCEOSale4,743$14.23$67.5KForm 4
Dec 2, 2025Kathleen S. CappsSee RemarksSale207$13.96$2.9KForm 4
Dec 2, 2025Harry R. Trout IIISee RemarksSale380$13.96$5.3KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jay R. LulyPresident and CEO, Director–$67.5KDec 5, 2025
Yat Sun OrChief Scientific Officer–$34KDec 5, 2025
Tara Lynn KiefferChief Product Strategy Officer–$30KDec 5, 2025
Brendan LuuChief Business Officer–$19.8KDec 5, 2025
Harry R. Trout IIISee Remarks–$13KDec 5, 2025
Scott T. RottinghausChief Medical Officer–$11.4KDec 5, 2025
Kathleen S. CappsSee Remarks–$7.5KDec 5, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ENTA short interest

Moderate short interest. 6.4% of ENTA shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went down 16%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.86M ENTA shares were sold short, 6.4% of the shares outstanding, down 18.0% from the report before. At the average daily volume of 243,263 shares, buying them all back would take about 7.6 trading days (days to cover).

Shares short, % of all shares

6.37%May 15Oct 309.62%

Days to cover

7.6May 15Oct 3019.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.86M6.37%-18%243,2637.6
Oct 15, 20262.27M7.78%-11%264,2558.6
Sep 30, 20262.55M8.77%-2%277,6859.2
Sep 15, 20262.60M8.93%-1%242,45110.7
Aug 31, 20262.62M8.98%-2%257,67210.2
Aug 14, 20262.68M9.20%+4%181,76214.7
Jul 31, 20262.59M8.90%+6%146,34817.7
Jul 15, 20262.44M8.40%-6%191,23912.8
Jun 30, 20262.58M8.88%+6%319,2848.1
Jun 15, 20262.43M8.35%+7%189,61212.8
May 29, 20262.27M7.82%+3%207,42111.0
May 15, 20262.20M7.58%+2%235,0349.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Enanta Pharmaceuticals company events

Enanta Pharmaceuticals filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 29, 2026.

  1. Oct 29, 2026AnnouncementAs previously disclosed, Enanta Pharmaceuticals, Inc. filed a patent infringement action in the Unified Patent Court of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determination of liability for infringement of European Patent No. EP 4 051 265 in connection… Filing
  2. Oct 28, 2026LeadershipEnanta Pharmaceuticals, Inc. and Jay R. Luly, Ph.D., age 70, announced Dr. Luly’s intention to retire as President and Chief Executive Officer by February 1, 2027, following 23 years of leadership with the Company. Filing
  3. Aug 10, 2026ResultsReleased financial results. Filing
  4. Jul 2, 2026AgreementEnanta Pharmaceuticals, Inc. entered into an Open Market Sale Agreement SM with Jefferies LLC, as sales agent, pursuant to which the Corporation may offer and sell shares of its common stock, $0.01 par value per share, from time to time through the Agent. Filing
  5. Jun 23, 2026AnnouncementAs previously disclosed by Enanta Pharmaceuticals, Inc., the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit relating to its suit against Pfizer Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 in the manufacture, use, and sale of… Filing
  6. Jun 18, 2026AnnouncementShared information with investors. Filing
  7. May 11, 2026ResultsReleased financial results. Filing
  8. Mar 26, 2026AnnouncementAs previously disclosed by Enanta Pharmaceuticals, Inc., on February 3, 2025, the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit relating to its suit against Pfizer Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 in the… Filing
  9. Mar 12, 2026LeadershipAs disclosed below under Item 5.07, on March 11, 2026, the stockholders of Enanta Pharmaceuticals, Inc. approved an amendment to its 2019 Equity Incentive Plan to increase the number of shares reserved for issuance thereunder by 1,600,000 shares. Filing
  10. Feb 9, 2026ResultsReleased financial results. Filing
  11. Nov 17, 2025ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Enanta Pharmaceuticals financials

Famous investors that hold ENTA

5 of the 50 well-known investors we track reported holding ENTA in their latest 13F filing. The largest position is Israel Englander's, worth $10.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026774,748$10.2M0.0%+20%
Jim Simons · Renaissance TechnologiesQ3 2026473,000$6.2M0.0%-15%
Ken Griffin · Citadel AdvisorsQ3 2026138,638$1.8M0.0%+173%
Steve Cohen · Point72 Asset ManagementQ3 202647,094$621K0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202610,443$138K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named ENTA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026ADAR1 Capital Management, LLC13G6.0%
Nov 16, 2026ADAR1 Capital Management, LLC13G6.0%
Nov 16, 2026Farallon Capital Management, L.L.C.13G/A3.3%
Nov 16, 2026Farallon Capital Management, L.L.C.13G/A3.3%
Oct 27, 2026BlackRock Portfolio Management LLC13G5.4%
Oct 27, 2026BlackRock Portfolio Management LLC13G5.4%

Questions about Enanta Pharmaceuticals Inc (ENTA) stock

Who owns the most ENTA stock?

The largest reported owner of Enanta Pharmaceuticals Inc (ENTA) is Jupiter Topco LLC, with 12.6% of the company. In total, 121 funds and institutions reported holding ENTA at the end of Q2 2026, together about 95% of the shares. See the largest owners.

Are ENTA insiders buying or selling?

In the last 12 months, ENTA insiders reported no open-market purchases and 9 sales worth $183K. The latest trade was on Dec 5, 2025. See every trade.

What is the short interest in ENTA?

As of Oct 30, 2026, 1.86M ENTA shares were sold short, 6.4% of the shares outstanding, down 18.0% from the report before. At the average daily volume of 243,263 shares, buying them all back would take about 7.6 trading days (days to cover). See the history.

Which famous investors hold ENTA?

5 of the 50 well-known investors we track reported ENTA in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $10.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.